We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Effect of Ambroxol in Diabetic Peripheral Neuropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05558878
Recruitment Status : Not yet recruiting
First Posted : September 28, 2022
Last Update Posted : September 29, 2022
Information provided by (Responsible Party):
Beshoy Thabit, Ain Shams University

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : October 2023
Estimated Study Completion Date : November 2023
Association, American Diabetes.
Soliman E,Gellido C.Diabetic Neuropathy. eMedicine.com March 29, 2002.
American Diabetes Association. Standardized measures in diabetic neuropathy. Diabetes Care 1996;19(1S):72S-92S.
Sheikh, W. M. E., Alahmar, I. E., Salem, G. M., & El-Sheikh, M. A. (2019). Tumor necrosis factor alpha in peripheral neuropathy in type 2 diabetes mellitus. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 55(1), 1-7. https://doi.org/10.1186/s41983-019-0080-0
Weiser T (2000) The secretolytic ambroxol blocks neuronal Na+channels. Soc Neurosci Abstr 454.14.